hims hers - Search News

Hims & Hers to offer at-home blood draws and lab testing

Hosted on MSN · 2h

Hims & Hers to offer at-home blood draws, lean into 'peptide innovations' with new acquisitions

The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

Investopedia on MSN · 1d

Hims & Hers Stock Hits Record High on Blood-Testing Lab Acquisition

Key Takeaways Shares of Hims & Hers Health touched a fresh record high in Wednesday trading after the company announced its latest acquisition.The company said it acquired Trybe Labs, which will help Hims launch an at-home blood drawing and lab testing service.

GlobalData on MSN · 1d

Hims & Hers to introduce at-home lab testing with Trybe Labs acquisition

Hims & Hers, a health and wellness platform, is set to introduce at-home lab testing capabilities through the acquisition of US-based Trybe Labs. This strategic move is set to enhance the company's ability to offer whole body testing and personalised healthcare solutions directly to customers.

Hims, Hers Stock

The Motley Fool on MSN · 23h

Why Hims & Hers Stock Dropped Today

Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) rating on Hims & Hers stock. Investors are taking the hint, and doing just that.

Money Morning · 2h

Why Is HIMS Stock Down So Much? Should You Buy?

HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which previously allowed Hims & Hers to sell compounded alternatives. Compounded versions were permitted during the shortage but are now restricted unless they meet specific exceptions.

SchaeffersResearch.com · 2h

Hims and Hers Stock Drops Weight as Earnings Loom

Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings

Analysts explain why Hims & Hers stock is crashing today

On Friday, shares of Hims&Hers Health Inc (NYSE:HIMS) dropped over 20% following an FDA announcement that the supply shortage of Novo Nordisk (NYSE:NVO)'s weight loss and diabetes drugs was ending.

23h

Hims & Hers Health (HIMS) Upward Trajectory Boosted by Recent Acquisition

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

Hims & Hers plunges as the FDA says Novo’s weight loss drugs are not in shortage

Hims & Hers Health (HIMS) stock falls as the FDA declares that Novo Nordisk's (NVO) weight loss therapies are no longer in ...

Hims & Hers Health Shares Tumble After Novo Nordisk Says Wegovy, Ozempic Shortage is Over

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

Hims & Hers acquires U.S.-based peptide facility in California

Hims & Hers announced it has acquired a U.S.-based peptide facility based in California. The company said the acquisition will enable the ...

Hims & Hers: A Glorious Opportunity To Trim (Rating Downgrade)

Hims & Hers Health, Inc. stock surged 1,000% with strategic growth, but high valuation & short interest suggest taking ...

24/7 Wall St. on MSN55m

Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?

Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...

Hims Expands Drug Manufacturing With California Peptide Plant Acquisition

Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Hims & Hers to offer at-home blood draws and lab testing

Hims, Hers Stock

Related topics